Af­ter rais­ing $158M, this up­start's founders have star back­ers and plans to break new ground in gene ther­a­py

Back in 2014, Stephanie Tagli­atela opt­ed to take an ear­ly ex­it out of her PhD pro­gram af­ter work­ing in Mark Bear’s lab at MIT, where she spe­cial­ized in the synap­tic con­nec­tions be­tween neu­ronal cells in the brain. She nev­er fin­ished that PhD, but she and fel­low MIT stu­dent Kar­tik Ra­mamoor­thi — who was on the found­ing team at Voy­ager — came away with some ideas for a gene ther­a­py start­up.

To­day, ful­ly 5 years lat­er, she and Ra­mamoor­thi are tak­ing the wraps off of a $104 mil­lion mega-round de­signed to take the cu­mu­la­tive work of their pre­clin­i­cal for­ma­tive stage for En­cod­ed Ther­a­peu­tics in­to hu­man stud­ies. They’ve now raised $158 mil­lion since start­ing out in Il­lu­mi­na’s in­cu­ba­tor in the Bay Area, and they be­lieve they are firm­ly on track to do some­thing unique in gene ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.